Sofosbuvir/ledipasvir plus ribavirin shows high cure rate for hepatitis C patients with advanced liver disease
Merck HCV combination achieves 90% cure in advanced cirrhosis
Merck HCV combination effective after failure of first generation of direct-acting antivirals
Treatment outcomes no better with single tablet regimens than individual tablets
HCV viral load levels during treatment and speed of decline do not predict cure with interferon-free therapy